Zacks Research Has Negative Outlook of Glaukos Q1 Earnings

Glaukos Corporation (NYSE:GKOS) – Equities researchers at Zacks Research lowered their Q1 2026 earnings estimates for shares of Glaukos in a report issued on Monday, March 9th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of ($0.27) for the quarter, down from their previous forecast of ($0.16). The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.67) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at $0.10 EPS, Q4 2027 earnings at $0.33 EPS and FY2027 earnings at $0.42 EPS.

Glaukos (NYSE:GKOS) last posted its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The firm had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.Glaukos’s revenue for the quarter was up 35.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) EPS.

Other equities analysts have also issued research reports about the stock. Truist Financial increased their target price on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Stephens upped their price objective on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 2nd. UBS Group raised their target price on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Glaukos from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $133.69.

Glaukos Stock Performance

Shares of GKOS stock opened at $103.05 on Wednesday. Glaukos has a 12-month low of $73.16 and a 12-month high of $130.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The firm has a market capitalization of $5.98 billion, a price-to-earnings ratio of -31.61 and a beta of 0.70. The business has a 50 day simple moving average of $115.41 and a 200 day simple moving average of $101.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GKOS. Janus Henderson Group PLC grew its holdings in shares of Glaukos by 183.4% in the 4th quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after buying an additional 1,953,578 shares during the period. Primecap Management Co. CA raised its holdings in Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after acquiring an additional 1,123,140 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Glaukos by 209.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after buying an additional 913,458 shares during the last quarter. Norges Bank acquired a new stake in Glaukos in the 2nd quarter valued at about $76,314,000. Finally, Millennium Management LLC raised its position in shares of Glaukos by 75.3% in the fourth quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock valued at $181,751,000 after purchasing an additional 691,289 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Insider Activity at Glaukos

In other news, Director Marc Stapley sold 15,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the completion of the transaction, the director owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. This represents a 28.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 10,498 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total value of $1,340,384.64. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at approximately $11,793,290.88. This represents a 10.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 320,000 shares of company stock worth $37,202,909. Insiders own 6.40% of the company’s stock.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks issued a FY2028 EPS forecast of $1.68 for Glaukos, signaling an expectation of material recovery and multi‑year profitability if the company hits that trajectory. This longer‑horizon upside may support investor optimism despite near‑term cuts. MarketBeat GKOS
• Neutral Sentiment: Despite the downward revisions, Zacks still models FY2027 EPS of $0.42 (return to profitability), indicating they view the company’s recovery as delayed rather than derailed — a mixed signal that could temper outright panic. MarketBeat GKOS
• Negative Sentiment: Zacks cut multiple near‑term estimates substantially: Q1–Q4 2026 and several 2027 quarter forecasts were reduced (examples: Q1 2026 from ($0.16) to ($0.27); Q2 2026 from ($0.12) to ($0.24); Q3 2026 from ($0.05) to ($0.15); FY2026 from ($0.29) to ($0.67); FY2027 from $0.78 to $0.42). These downgrades imply weaker near‑term profitability and raise the bar for upcoming quarters, which likely pressured the stock today. MarketBeat GKOS

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.